Published in Chest on March 01, 1999
Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformans. Mol Cell Biol (2001) 3.11
Cavitary pulmonary disease. Clin Microbiol Rev (2008) 2.31
Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status. PLoS One (2013) 1.23
Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis (2008) 1.20
The prevalence and clinical course of HIV-associated pulmonary cryptococcosis in Uganda. J Acquir Immune Defic Syndr (2010) 1.13
The copper regulon of the human fungal pathogen Cryptococcus neoformans H99. Mol Microbiol (2011) 1.08
Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis (2008) 0.95
Pulmonary cryptococcosis: imaging findings in 23 non-AIDS patients. Korean J Radiol (2010) 0.93
Interleukin-17A enhances host defense against cryptococcal lung infection through effects mediated by leukocyte recruitment, activation, and gamma interferon production. Infect Immun (2013) 0.93
Cryptococcus infection in tropical Australia. J Clin Microbiol (2004) 0.92
Contribution of the mannan backbone of cryptococcal glucuronoxylomannan and a glycolytic enzyme of Staphylococcus aureus to contact-mediated killing of Cryptococcus neoformans. J Bacteriol (2007) 0.89
Pulmonary cryptococcosis with cryptococcal meningitis in an immunocompetent host. Lung India (2014) 0.87
A case of pulmonary cryptococcosis by capsule-deficient Cryptococcus neoformans. Korean J Intern Med (2006) 0.84
Cryptococcal lung disease in patients without HIV infection. Chest (1999) 0.81
The RGS protein Crg2 is required for establishment and progression of murine pulmonary cryptococcosis. Med Mycol (2010) 0.76
Pulmonary Cryptococcosis in the Immunocompetent Patient-Many Questions, Some Answers. Open Forum Infect Dis (2016) 0.75
Cryptococcal sepsis in small vessel vasculitis. Indian J Nephrol (2010) 0.75
A typical atypical pneumonia. Can J Infect Dis (2002) 0.75
Pulmonary cryptococcosis that mimicked rheumatoid nodule in rheumatoid arthritis lesion. Tuberc Respir Dis (Seoul) (2014) 0.75
Pulmonary cryptococcosis manifesting as diffuse air-space consolidations in an immunocompetent patient. J Thorac Dis (2017) 0.75
Surgical Resection during Chemotherapy of Pulmonary Cryptococcoma in a Patient with Cryptococcal Meningitis. Intern Med (2017) 0.75
Cavitating pneumonia after treatment with infliximab and prednisone. Eur J Clin Microbiol Infect Dis (2004) 0.75
Community-acquired pneumonia. N Engl J Med (1995) 6.12
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
Sex differences in nevirapine rash. Clin Infect Dis (2000) 2.09
Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis (2000) 1.95
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 1.89
Amphotericin B: delivery systems. Antimicrob Agents Chemother (1990) 1.78
Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clin Infect Dis (1993) 1.77
Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection (2007) 1.72
Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? Bone Marrow Transplant (2006) 1.67
Enteric carriage of vancomycin-resistant Enterococcus faecium in patients tested for Clostridium difficile. Infect Control Hosp Epidemiol (1999) 1.61
Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr (1999) 1.61
Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis (1998) 1.60
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med (1995) 1.59
Cloning and characterization of the Bacteroides fragilis metalloprotease toxin gene. Infect Immun (1997) 1.58
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Bacteremia in hospitalized patients infected with the human immunodeficiency virus: a case-control study of risk factors and outcome. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.47
Sexually transmitted disease acquisition among women infected with human immunodeficiency virus type 1. J Infect Dis (1998) 1.43
Non-neoformans cryptococcal infections: a systematic review. Infection (2007) 1.39
The CASE adherence index: A novel method for measuring adherence to antiretroviral therapy. AIDS Care (2006) 1.39
Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett (1994) 1.38
Prophylaxis and treatment of opportunistic infection in patients on HAART. AIDS Read (2003) 1.38
Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis (2000) 1.34
Rapid characterization schemes for surveillance isolates of vancomycin-resistant enterococci. J Clin Microbiol (1997) 1.34
Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients. AIDS (1992) 1.29
Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. Am J Physiol (1998) 1.27
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J Acquir Immune Defic Syndr (1994) 1.22
Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia. Am J Physiol Endocrinol Metab (2005) 1.21
Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med (2006) 1.21
Evaluation of a latex agglutination test for Clostridium difficile in two nursing home outbreaks. J Clin Microbiol (1989) 1.20
Diagnosis of Chlamydia pneumoniae infection in patients with community-acquired pneumonia by polymerase chain reaction enzyme immunoassay. Clin Infect Dis (1994) 1.18
Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS (1999) 1.15
Patterns of opportunistic infections in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.13
Antiretroviral drug resistance among antiretroviral-naïve persons with recent HIV infection in Thailand. HIV Med (2008) 1.13
Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis (2000) 1.12
Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med (1993) 1.11
Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma. J Clin Microbiol (1995) 1.10
Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Arch Intern Med (1998) 1.09
Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1992) 1.09
Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. J Infect Dis (1995) 1.07
Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab (2003) 1.06
Exposure of mice to live Pseudomonas aeruginosa generates protective cell-mediated immunity in the absence of an antibody response. J Immunol (1988) 1.05
Acquisition of vancomycin-resistant enterococci during scheduled antimicrobial rotation in an intensive care unit. Clin Infect Dis (2001) 1.04
Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis (1999) 1.02
Pneumococcal endocarditis: report of a series and review of the literature. Rev Infect Dis (1986) 1.02
Disclosure of HIV status to medical providers: differences by gender, "race," and immune function. Public Health Rep (2000) 1.01
Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis (1995) 1.00
Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review. Clin Microbiol Infect (2009) 1.00
Variations in healthcare measures by insurance status for patients receiving ventilator support. Clin Perform Qual Health Care (1998) 1.00
Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. AIDS (2000) 1.00
Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: a case-control study. Clin Infect Dis (1994) 0.97
T lymphocyte-mediated protection against Pseudomonas aeruginosa infection in granulocytopenic mice. J Clin Invest (1986) 0.96
Isoniazid preventive therapy and 4-year incidence of pulmonary tuberculosis among HIV-infected Thai patients. Int J Tuberc Lung Dis (2012) 0.96
Fellowship training in infectious diseases: a report from the regional and national meetings of infectious diseases division chiefs and program directors. Clin Infect Dis (1998) 0.96
Contraceptive use and pregnancy decision making among women with HIV. AIDS Patient Care STDS (1999) 0.96
Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J Appl Physiol (1985) (2001) 0.95
Two cases of blastomycosis from a common source: use of DNA restriction analysis to identify strains. J Infect Dis (1991) 0.94
Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. Am J Med (2001) 0.92
Sources influencing patients in their HIV medication decisions. Health Educ Behav (2001) 0.92
Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J Infect Dis (1992) 0.91
Tuberculin skin test reactivity, anergy, and HIV infection in hospitalized patients. Longcope Firm of the Osler Medical Housestaff. Am J Med (1996) 0.91
Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome. HIV Med (2009) 0.90
Cryptococcal disease: implications of recent clinical trials on treatment and management. AIDS Clin Rev (1997) 0.89
Factors associated with HIV-infected patients' recognition and use of HIV medications. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 0.88
Suppressor T cells regulating the cell-mediated immune response to Pseudomonas aeruginosa can be generated by immunization with anti-bacterial T cells. J Immunol (1988) 0.87
The changing face of mycoses in patients with HIV/AIDS. AIDS Read (2001) 0.87
Changes in plasma amino acid concentrations in response to HIV-1 infection. Clin Chem (1994) 0.87
Post-exercise heart rate recovery in HIV-positive individuals on highly active antiretroviral therapy. Early indicator of cardiovascular disease? HIV Med (2007) 0.87
USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Clin Infect Dis (1995) 0.86
Women with HIV: conflicts and synergy of prayer within the realm of medical care. AIDS Educ Prev (2000) 0.85
Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat (2007) 0.85
Editorial response: management of cryptococcal meningitis--have we answered all the questions? Clin Infect Dis (1996) 0.84
Hot tub legionellosis. Legionnaires' disease and Pontiac fever after a point-source exposure to Legionella pneumophila. Arch Intern Med (1993) 0.84
In vitro T cell-mediated killing of Pseudomonas aeruginosa. V. Generation of bactericidal T cells in nonresponder mice. J Immunol (1987) 0.84
Rapid diagnosis of Chlamydia psittaci pneumonia. Clin Infect Dis (1993) 0.83
Hypothalamic-pituitary-adrenal function in patients receiving intermittent high dose prednisone therapy for lymphoma. Ir Med J (1984) 0.83
In vitro T cell-mediated killing of Pseudomonas aeruginosa. IV. Nonresponsiveness in polysaccharide-immunized BALB/c mice is attributable to vinblastine-sensitive suppressor T cells. J Immunol (1986) 0.83
Nelfinavir mesylate. Expert Opin Pharmacother (2000) 0.82
Renal glomerulopathies associated with Hodgkin's disease. Cancer (1985) 0.82
Evaluation of zinc bacitracin capsules versus placebo for enteric eradication of vancomycin-resistant Enterococcus faecium. Clin Infect Dis (2001) 0.82
Risks of HIV infection in the health care setting. Annu Rev Med (1995) 0.82
Utilization of computed tomography in patients hospitalized with community-acquired pneumonia. Md Med J (1998) 0.81
Serum leptin concentrations in human immunodeficiency virus-infected men with low adiposity. Metabolism (1997) 0.81
Cryptococcosis. Adv Pharmacol (1997) 0.81
Acute flaccid paralysis syndrome associated with echovirus 19, managed with pleconaril and intravenous immunoglobulin. Clin Infect Dis (2001) 0.81
Alterations in spliced and unspliced HIV-1-specific RNA detection in peripheral blood mononuclear cells of individuals with varying CD4-positive lymphocyte counts. AIDS Res Hum Retroviruses (1993) 0.81
In vitro T cell-mediated killing of Pseudomonas aeruginosa. III. The role of suppressor T cells in nonresponder mice. J Immunol (1986) 0.80
Women's HIV transmission risk perceptions and behaviors in the era of potent antiretroviral therapies. AIDS Educ Prev (2001) 0.80
Oesophageal ulceration in Behçet's disease presenting with haemorrhage. Ir J Med Sci (1987) 0.80
The use of alternative therapies by HIV-positive patients attending the St. Louis AIDS Clinical Trials Unit. Mo Med (1991) 0.79
Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. Am J Med (1993) 0.79